Current Diabetes Reports
- Print ISSN
- Electronic ISSN
- Impact factor
- Usage rank
- Article count
- Free count
- Free percentage
- PDFs via platforms
- Metapress, Gale, and Springer
Risks and benefits of statin use in young people with type 1 diabetes.
We will summarize the risks and benefits of statin use in young people with T1D....
Risk vs benefit in diabetes pharmacotherapy: a rational approach to choosing pharmacotherapy in type 2 diabetes.
We review the commonly prescribed pharmacotherapy options with attention to recently published information and provide a rational approach to choice of therapy....
Novel targets against retinal angiogenesis in diabetic retinopathy.
Proliferative diabetic retinopathy (PDR), characterized by pathologic retinal angiogenesis, is a major cause of blindness in the USA and globally. Treatments targeting vascular endothelial growth factor (VEGF) have emerged as a beneficial part of the therapeutic armamentarium for this condition, hig...
Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.
Blockade of the renin-angiotensin-aldosterone system (RAAS) prevents the development and progression of diabetic kidney disease (DKD). It is controversial whether the simultaneous use of two RAAS inhibitors (ie, dual RAAS blockade) further improves renal outcomes. This review examines the scientific...
Current concepts about chromium supplementation in type 2 diabetes and insulin resistance.
Best strategies for hypertension management in type 2 diabetes and obesity.
The Eurodiab study: what has this taught us about diabetic peripheral neuropathy?
Apart from tight blood glucose control, no other treatments have been shown to retard the progression of diabetic peripheral neuropathy (DPN). Therefore, identifying potential risk factors for DPN is important, particularly if they are modifiable. The Eurodiab baseline DPN study found a prevalence o...
Aldosterone and diabetic kidney disease.
Aldosterone plays an important role in salt and water homeostasis and blood pressure control through the classical mineralocorticoid receptor. However, recent findings of the mineralocorticoid receptor in nonepithelial tissues suggest that aldosterone may have additional functions. Significant evide...
Treatment of hypertension in metabolic syndrome: implications of recent clinical trials.
Metabolic syndrome represents a constellation of hypertension, abdominal obesity, impaired fasting glucose, and dyslipidemia, and it has been shown to be a risk factor for cardiovascular disease. The components of metabolic syndrome are rapidly emerging as epidemics of the twenty-first century, and...
Diabetic dyslipidemia and cardiovascular risk.